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Kidney stones? It’s time  
to rethink those meds 
Despite being recommended for ureteral stone 
expulsion, tamsulosin or nifedipine are no more  
effective than placebo.
PRACTICE CHANGER
Do not prescribe tamsulosin or nifedipine 
for stone expulsion in patients with ureteral 
stones ≤10 mm.1 
STRENGTH OF RECOMMENDATION
A: Based on a high-quality randomized con-
trolled trial.
Pickard R, Starr K, MacLennan G, et al. Medical expulsive therapy 
in adults with ureteric colic: a multicentre, randomised, placebo- 
controlled trial. Lancet. 2015;386:341-349.
ILLUSTRATIVE CASE
Bob Z, age 48, presents to the emergency de-
partment (ED) with unspecified groin pain. 
A computed tomography scan of the kidney, 
ureter, and bladder (CT KUB) finds evidence of 
a single ureteral stone measuring 8 mm. He’s 
prescribed medication for the pain and dis-
charged. The day after his ED visit, he comes 
to your office to discuss further treatment op-
tions. Should you prescribe tamsulosin or nife-
dipine to help him pass the stone?
The most recent National Health and Nutrition Examination Survey found kidney stones affect 8.8% of the popu-
lation.2 Outpatient therapy is indicated for 
patients with ureteric colic secondary to 
stones ≤10 mm who do not have uncontrolled 
pain, impaired kidney function, or severe in-
fection. Routine outpatient care includes 
oral hydration, antiemetics, and pain medi-
cations. Medical expulsive therapy (MET) is 
also used to facilitate stone passage. MET is 
increasingly becoming part of routine care; 
use of MET in kidney stone patients in the 
United States has grown from 14% in 2009 to 
64% in 2012.3,4 
The joint European Association of Urol-
ogy/American Urological Association Neph-
rolithiasis Guideline Panel supports the use 
of MET.5 Meta-analyses of multiple random-
ized controlled trials (RCTs) suggest that 
an alpha-blocker (tamsulosin) or a calcium 
channel blocker (nifedipine) can reduce 
pain and lead to quicker stone passage and 
a higher rate of eventual stone passage when 
compared to placebo or observation.6,7 How-
ever, these reviews included small, hetero-
geneous studies with a high or unclear risk 
of bias. 
STUDY SUMMARY
MET doesn’t increase the rate  
of stone passage
The SUSPEND (Spontaneous Urinary Stone 
Passage ENabled by Drugs) trial1 was a multi-
center RCT designed to determine the effec-
tiveness of tamsulosin or nifedipine as MET 
for patients ages 18 to 65 years with a single 
ureteric stone measuring ≤10 mm on CT 
KUB, which has 98% diagnostic accuracy.8 
(Stones >10 mm typically require surgery or 
lithotripsy.)
In this RCT, 1167 adults were random-
ized to take tamsulosin 0.4 mg/d, nifedip-
ine 30 mg/d, or placebo for 4 weeks or until 
the stone spontaneously passed, whichever 
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came first. The participants, clinicians, and 
research staff were blinded to treatment as-
signment. The primary outcome was the pro-
portion of participants who spontaneously 
passed their stone, as indicated in patient 
self-reported questionnaires and case-report 
forms completed by researchers. Secondary 
outcomes were time to stone passage and 
pain as assessed by analgesic use and a visual 
analogue scale (VAS).
At 4 weeks, 1136 (97%) of the randomized 
participants had data available for analysis. 
The proportion of participants who passed 
their stone did not differ between MET and 
placebo; 80% of the placebo group (303 of 
379 participants) passed the stone, compared 
with 81% (307 of 378) of the tamsulosin group 
and 80% (304 of 379) of the nifedipine group. 
The odds ratio (OR) for MET vs placebo was 
1.04 (95% confidence interval [CI], 0.77 to 
1.43) and the OR for tamsulosin vs nifedipine 
was 1.07 (95% CI, 0.74 to 1.53). These findings 
did not change with further subgroup analy-
sis, including by sex, stone size (≤5 mm vs 
>5 mm), or stone location.
There were no differences between 
groups in time to stone passage as measured 
by clinical report and confirmed by imag-
ing. Time to passage of stone was available 
for 237 (21%) of participants. The mean 
days to stone passage was 15.9 (n=84) for 
placebo, 16.5 (n=79) for tamsulosin and 
16.2 (n=74) for nifedipine, with a MET vs pla-
cebo difference of 0.5 days (95% CI, -2.9 to 
3.9; P=.78). Sensitivity analysis accounting 
for bias from missing data did not change this 
outcome.
❚ No differences in analgesic use or 
pain.  Self-reported use of pain medication 
during the first 4 weeks was similar between 
groups: 59% (placebo patients), 56% (tamsu-
losin), and 56%  (nifedipine). The mean days 
of pain medication use was 10.5 for placebo, 
11.6 for tamsulosin, and 10.7 for nifedipine, 
with a MET vs placebo difference of 0.6 days 
(95% CI, -1.6 to 2.8; P=.45). 
There was no difference between groups 
in the VAS pain score at 4 weeks. The MET 
vs placebo difference was 0.0 (95% CI, -0.4 
to 0.4; P=.96) and the mean VAS pain score 
was 1.2 for placebo, 1.0 for tamsulosin, and 
1.3 for nifedipine.
WHAT’S NEW
This large RCT contradicts results  
from previous meta-analyses
The SUSPEND study is the first large, multi-
center RCT of MET with tamsulosin or 
nifedipine for kidney stones that used patient-
oriented outcomes to find no benefit for stone 
expulsion, analgesic use, or reported pain 
compared to placebo. The discrepancy with 
prior meta-analyses is not unusual. Up to one-
third of meta-analyses that show positive out-
comes of a therapy are subsequently altered 
by the inclusion of results from a single, large, 
multicenter, well-designed RCT.9 
CAVEATS
This trial included fewer women  
than previous studies
The SUSPEND study included a smaller pro-
portion of women than previously published 
case series due to a need for a diagnostic CT 
KUB, which excluded more women than men 
due to radiation concerns. However, the pro-
portion of women was balanced across all 
groups in this trial, and there was no evidence 
that sex impacted the efficacy of treatment for 
the primary outcome.1
CHALLENGES TO IMPLEMENTATION
We see no challenges to the implementation 
of this recommendation.                 JFP
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